



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

RTS-0335

Inventors:

Kenneth W. Dobie

Serial No.:

10/006,972

Filing Date:

December 4, 2001

Examiner:

Not Yet Assigned

Group Art Unit:

1633

Title:

Antisense Modulation of
Phospholipid Scramblase 3
Expression

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202.

On this date: May 21, 2002

Kathleen A. Tyrrell, Registration No. 38,350

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Dear Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Enclosed for your information is a copy of the Filing Receipt issued by the PTO with respect to the above-identified application. You will note that the following items require correction:

In the **Atty. Docket No.:**

Please delete "RST-0335" and insert --RTS-0335--.

RECEIPT
#7/R.T.
7/22
CFR
RECEIVED
JUN 05 2002
TECH CENTER 1600/2900

Since this appears to be an error on the part of the United States Patent and Trademark Office, it is respectfully requested that a corrected filing receipt be issued in this case.

Respectfully submitted,




Kathleen A. Tyrrell
Registration No. 38,350

Date: May 21, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/006,972	12/04/2001	1633	370	RST-0335		20	2

RTS-0335

CONFIRMATION NO. 2850

FILING RECEIPT

RECEIVED



OC00000007566172

JUN 05 2002

TECH CENTER 1600/2900

Date Mailed: 03/01/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kenneth W. Dobie, Del Mar, CA;

Assignment For Published Patent Application

Isis Pharmaceuticals Inc.;

Domestic Priority data as claimed by applicant**Foreign Applications****If Required, Foreign Filing License Granted** 03/01/2002**Projected Publication Date:** To Be Determined - pending completion of Sequence Disclosures**Non-Publication Request:** No**Early Publication Request:** No**** SMALL ENTITY ******Title**

Antisense modulation of phospholipid scramblase 3 expression

Preliminary Class

435



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

RECEIVED

JUN 6 2002

GRANTED**TECH CENTER 1000/2000**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).